André-Jacques Auberton-Hervé
President, CEO and Chairman @ Soitec
Grenoble, France
André-Jacques Auberton-Hervé is a seed investor at Soitec in Grenoble focused on Medical and Biotechnology. Dr. André-Jacques Auberton-Hervé co-founded Soitec with Jean-Michel Lamure in 1992. As President, CEO and Chairman of the Board, Auberton-Hervé is responsible for overseeing the strategic, operational and financial activities of the company.Prior to founding Soitec, Auberton-Hervé managed several joint development programs between Leti andThomson-CSF, which focused on the technological transfer from R&D to production applications. These programs included the transfer of 1.2 µm and 0.8 µm SOI CMOS for space applications. He was also in charge of several projects, which applied SOI to 3D integration, VLSI and ULSI.In July of 2005, Auberton-Hervé was elected to serve as the European representative to SEMI’s International Board of Directors. His demonstrated vision, experience and leadership capabilities within the industry contributed to his appointment to the board. Auberton-Hervé is also the recipient of the 1999 European SEMI Award in recognition of his work on Smart Cutâ„¢ technology and his overall contributions to the semiconductor industry as a whole. Auberton-Hervé is a member of the Electrochemical Society and the IEEE.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries André-Jacques Auberton-Hervé invests in
Stages André-Jacques Auberton-Hervé invests in
Countries André-Jacques Auberton-Hervé invests in
Investment Focus
Industry
- Medical 1 (50%)
- Biotechnology 1 (50%)
Stage
- Seed 1 (50%)
- Series A 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LinKinVax
|
LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). | $7.8M / Series A / Jan 09, 2023 | |
|
LinKinVax
|
LinKinVax operates as a clinical-stage biotechnology company. LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). | $5M / Seed / Feb 10, 2022 |
Co-Investors
About Soitec
For more than a decade, Soitec has helped IC manufacturers reap the benefits of silicon-on-insulator (SOI) wafers on an industrial scale, thanks to its unique Smart Cut™ technology, which is key to producing these advanced substrates in volume quantities. Today, the company is the world’s leading supplier of SOI wafers, as well as an innovationleader in this important growth market–serving as a catalyst for collaboration and materials innovation in SOI and other engineered substrates. Soitec leverages its patented Smart Cut technology to manufacture a comprehensive portfolio of SOI and other engineered substrates. With its proven ability to deliver competitive production advantages, as well as the productivity needed to support mass SOI adoption, Smart Cut has enabled Soitec to further strengthen its position as the technological and industrial leader at a time when the market is seeing extremely strong growth.
Soitec Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
André-Jacques Auberton-Hervé
President, CEO and Chairman
|
|||
Alain Delpy
Business Development Manager Imager, Silicon Photonics, MEMS
|
|||
|
André-Jacques Auberton-Hervé
President, CEO and Chairman
|
|||
Carlos Mazure
Chief Technology Officer
|
|||
Iain Murray
Chief Financial Officer (CFO)
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does André-Jacques Auberton-Hervé invest in?
André-Jacques Auberton-Hervé invests primarily in Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did André-Jacques Auberton-Hervé last invest?
The most recent investment recorded for André-Jacques Auberton-Hervé closed in Jan 2023. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
